Huonland Pharmaceutical Completes Incorporation Restructuring with Registered Capital of RMB 88.67 Million

Recently, BeijingNorthlandBeijing Northland Biotechnology Co., Ltd. (Stock Code: 430047, Stock Abbreviation: Northland) announced (Announcement No.: 2025-055) that its holding subsidiary, Beijing Hui'en Land Pharmaceutical Co., Ltd., has completed the shareholding system reform, and has been wholly transformed into Beijing Hui'en Land Pharmaceutical Co., Ltd., with all relevant industrial and commercial change registration procedures completed.

On August 11, 2025, Northland convened the 20th meeting of the Sixth Board of Directors, during which the "Proposal on the Subsidiary's Shareholding System Restructuring" was reviewed and approved. The meeting agreed to restructure Hui'en Land into a shareholding system and transform it into a joint-stock company. The relevant specific content has been disclosed on the Beijing Stock Exchange's official website on the same day (Announcement No.: 2025-049).

Currently, HuiEnLanDe has obtained the "Business License" issued by the Tongzhou District Market Supervision Administration of Beijing, with the following registration details:

The announcement shows that the file for reference is the "Business License of Beijing Hui'en Land Pharmaceutical Co., Ltd."

Click to view the original announcement>>

Statement: The market carries risks, and investments should be made with caution.This article is automatically published by a large AI model based on a third-party database. Any information appearing in this article (including but not limited to individual stock recommendations, comments, forecasts, charts, indicators, theories, or any form of expression, etc.) is for reference only and does not constitute personal investment advice. Due to issues such as the quality of the third-party database, we are unable to verify or ensure the authenticity and completeness of the data. Therefore, the content of this article may contain inaccuracies, incompleteness, or misleading information. Please refer to official company announcements for specific details. If you have any questions, please contact biz@staff.sina.com.cn.

Editor: Xiaolang Express